196 related articles for article (PubMed ID: 37195970)
1. Impact of valganciclovir therapy on severe IRIS-Kaposi Sarcoma mortality: An open-label, parallel, randomized controlled trial.
Volkow P; Chavez Galan L; Ramon-Luing L; Cruz-Velazquez J; Cornejo-Juarez P; Sada-Ovalle I; Perez-Padilla R; Islas-Muñoz B;
PLoS One; 2023; 18(5):e0280209. PubMed ID: 37195970
[TBL] [Abstract][Full Text] [Related]
2. Clinical characteristics, predictors of immune reconstitution inflammatory syndrome and long-term prognosis in patients with Kaposi sarcoma.
Volkow P; Cesarman-Maus G; Garciadiego-Fossas P; Rojas-Marin E; Cornejo-Juárez P
AIDS Res Ther; 2017 May; 14(1):30. PubMed ID: 28558783
[TBL] [Abstract][Full Text] [Related]
3. Predictors of immune reconstitution inflammatory syndrome-associated with kaposi sarcoma in mozambique: a prospective study.
Letang E; Almeida JM; Miró JM; Ayala E; White IE; Carrilho C; Bastos R; Nhampossa T; Menéndez C; Campbell TB; Alonso PL; Naniche D
J Acquir Immune Defic Syndr; 2010 Apr; 53(5):589-97. PubMed ID: 19801945
[TBL] [Abstract][Full Text] [Related]
4. Immune reconstitution inflammatory syndrome associated with Kaposi sarcoma: higher incidence and mortality in Africa than in the UK.
Letang E; Lewis JJ; Bower M; Mosam A; Borok M; Campbell TB; Naniche D; Newsom-Davis T; Shaik F; Fiorillo S; Miro JM; Schellenberg D; Easterbrook PJ
AIDS; 2013 Jun; 27(10):1603-13. PubMed ID: 23462220
[TBL] [Abstract][Full Text] [Related]
5. Valganciclovir modulates the tumor necrosis factor axis molecules expression and CD4+ T-cell subsets in disseminated Kaposi Sarcoma patients.
Ramon-Luing LA; Flores-Gonzalez J; Angel García-Rojas L; Islas-Muñoz B; Volkow-Fernández P; Chavez-Galan L
Clin Exp Immunol; 2024 Feb; 215(2):190-201. PubMed ID: 37904542
[TBL] [Abstract][Full Text] [Related]
6. Early Progression and Immune Reconstitution Inflammatory Syndrome During Treatment of Mild-To-Moderate Kaposi Sarcoma in Sub-Saharan Africa and South America: Incidence, Long-Term Outcomes, and Effects of Early Chemotherapy.
Nyirenda M; Ngongondo M; Kang M; Umbleja T; Krown SE; Godfrey C; Samaneka W; Mngqibisa R; Hoagland B; Mwelase N; Caruso S; Martinez-Maza O; Dittmer DP; Borok M; Hosseinipour MC; Campbell TB;
J Acquir Immune Defic Syndr; 2020 Aug; 84(4):422-429. PubMed ID: 32265361
[TBL] [Abstract][Full Text] [Related]
7. A Fatal Case of Kaposi Sarcoma Immune Reconstitution Syndrome (KS-IRIS) Complicated by Kaposi Sarcoma Inflammatory Cytokine Syndrome (KICS) or Multicentric Castleman Disease (MCD): A Case Report and Review.
Dumic I; Radovanovic M; Igandan O; Savic I; Nordstrom CW; Jevtic D; Subramanian A; Ramanan P
Am J Case Rep; 2020 Dec; 21():e926433. PubMed ID: 33268763
[TBL] [Abstract][Full Text] [Related]
8. Use of boosted protease inhibitors reduces Kaposi sarcoma incidence among male veterans with HIV infection.
Kowalkowski MA; Kramer JR; Richardson PR; Suteria I; Chiao EY
Clin Infect Dis; 2015 May; 60(9):1405-14. PubMed ID: 25586682
[TBL] [Abstract][Full Text] [Related]
9. Successful treatment of an HIV-positive patient with unmasking Kaposi's sarcoma immune reconstitution inflammatory syndrome.
Speicher DJ; Sehu MM; Johnson NW; Shaw DR
J Clin Virol; 2013 Jul; 57(3):282-5. PubMed ID: 23578530
[TBL] [Abstract][Full Text] [Related]
10. As-Needed Vs Immediate Etoposide Chemotherapy in Combination With Antiretroviral Therapy for Mild-to-Moderate AIDS-Associated Kaposi Sarcoma in Resource-Limited Settings: A5264/AMC-067 Randomized Clinical Trial.
Hosseinipour MC; Kang M; Krown SE; Bukuru A; Umbleja T; Martin JN; Orem J; Godfrey C; Hoagland B; Mwelase N; Langat D; Nyirenda M; MacRae J; Borok M; Samaneka W; Moses A; Mngqbisa R; Busakhala N; Martínez-Maza O; Ambinder R; Dittmer DP; Nokta M; Campbell TB;
Clin Infect Dis; 2018 Jul; 67(2):251-260. PubMed ID: 29365083
[TBL] [Abstract][Full Text] [Related]
11. Clinical characteristics and outcomes of HIV-infected children diagnosed with Kaposi sarcoma in Malawi and Botswana.
Cox CM; El-Mallawany NK; Kabue M; Kovarik C; Schutze GE; Kazembe PN; Mehta PS
Pediatr Blood Cancer; 2013 Aug; 60(8):1274-80. PubMed ID: 23487320
[TBL] [Abstract][Full Text] [Related]
12. Human immunodeficiency virus-associated Kaposi sarcoma as an immune reconstitution inflammatory syndrome: a literature review and case report.
Feller L; Anagnostopoulos C; Wood NH; Bouckaert M; Raubenheimer EJ; Lemmer J
J Periodontol; 2008 Feb; 79(2):362-8. PubMed ID: 18251652
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the human herpesvirus 8 DNA load in blood and Kaposi's sarcoma skin lesions from AIDS patients on highly active antiretroviral therapy.
Boivin G; Gaudreau A; Routy JP
AIDS; 2000 Sep; 14(13):1907-10. PubMed ID: 10997393
[TBL] [Abstract][Full Text] [Related]
14. A randomized controlled trial of highly active antiretroviral therapy versus highly active antiretroviral therapy and chemotherapy in therapy-naive patients with HIV-associated Kaposi sarcoma in South Africa.
Mosam A; Shaik F; Uldrick TS; Esterhuizen T; Friedland GH; Scadden DT; Aboobaker J; Coovadia HM
J Acquir Immune Defic Syndr; 2012 Jun; 60(2):150-7. PubMed ID: 22395672
[TBL] [Abstract][Full Text] [Related]
15. The effects of human herpesvirus 8 infection and interferon-gamma response in cutaneous lesions of Kaposi sarcoma differ among human immunodeficiency virus-infected and uninfected individuals.
Guedes F; de Andrade HF; Fernandes ER; Tuon FF; Brasil RA; Pagliari C; Duarte MI
Br J Dermatol; 2008 Sep; 159(4):839-46. PubMed ID: 18644020
[TBL] [Abstract][Full Text] [Related]
16. Immune Reconstitution Inflammatory Syndrome Associated Kaposi Sarcoma.
Poizot-Martin I; Brégigeon S; Palich R; Marcelin AG; Valantin MA; Solas C; Veyri M; Spano JP; Makinson A
Cancers (Basel); 2022 Feb; 14(4):. PubMed ID: 35205734
[TBL] [Abstract][Full Text] [Related]
17. Therapy of special HIV-associated diseases: HCV-HIV-co-infection and AIDS-related Kaposi's sarcoma - official satellite to the 7th European Conference on Clinical Aspects and Treatment of HIV-infection, October 23, 1999 in Lisbon, Portugal.
Goebel FD; Jablonowski H
Eur J Med Res; 1999 Dec; 4(12):507-13. PubMed ID: 10611054
[TBL] [Abstract][Full Text] [Related]
18. Steroids are a risk factor for Kaposi's sarcoma-immune reconstitution inflammatory syndrome and mortality in HIV infection.
Fernández-Sánchez M; Iglesias MC; Ablanedo-Terrazas Y; Ormsby CE; Alvarado-de la Barrera C; Reyes-Terán G
AIDS; 2016 Mar; 30(6):909-14. PubMed ID: 26636923
[TBL] [Abstract][Full Text] [Related]
19. Changing Incidence and Risk Factors for Kaposi Sarcoma by Time Since Starting Antiretroviral Therapy: Collaborative Analysis of 21 European Cohort Studies.
Cancer Project Working Group for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study in EuroCoord
Clin Infect Dis; 2016 Nov; 63(10):1373-1379. PubMed ID: 27535953
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of plasma human herpesvirus 8 DNA as a marker of clinical outcomes during antiretroviral therapy for AIDS-related Kaposi sarcoma in Zimbabwe.
Borok M; Fiorillo S; Gudza I; Putnam B; Ndemera B; White IE; Gwanzura L; Schooley RT; Campbell TB
Clin Infect Dis; 2010 Aug; 51(3):342-9. PubMed ID: 20572760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
